Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice

Claudia Palladino, María Luisa Navarro Gómez, Pere Soler-Palacín, María Isabel González-Tomé, Santiago J. De Ory, María Espiau, Santiago Pérez Hoyos, Juan Antonio León-Leal, María Méndez, David Moreno-Pérez, Claudia Fortuny Guasch, Antoni Mur Sierra, Itziar Pocheville Guruceta, Santiago Moreno Guillén, Verónica Briz

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


© Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
Original languageEnglish
Pages (from-to)2155-2159
Issue number16
Publication statusPublished - 23 Oct 2015


  • adolescents
  • children
  • HIV-1
  • maraviroc


Dive into the research topics of 'Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice'. Together they form a unique fingerprint.

Cite this